Form 4: Cynthia Smith, Agios Pharmaceuticals Director, Reports Stock and Options Grant

Director Cynthia Smith reports acquisition of restricted stock units and stock options in Agios Pharmaceuticals.

Summary

• On June 20, 2024, Cynthia Smith, a director of Agios Pharmaceuticals, acquired 2,120 restricted stock units and 11,774 stock options.
• The restricted stock units vest on June 20, 2025, and will be delivered within three business days after vesting.
• The stock options, with an exercise price of $42.45, also vest on June 20, 2025, and expire on June 20, 2034.
• Following these transactions, Smith directly owns 2,120 restricted stock units and 11,774 stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reports a standard transaction of stock and option grants to a director, which is a normal part of executive compensation.

Positives

• The grant of restricted stock units and stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the director.

Industry Context

Stock grants and options are common forms of executive compensation in the pharmaceutical industry, aligning management interests with shareholder value.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors in publicly traded companies, particularly in the biotech and pharmaceutical sectors.
• Companies like Vertex Pharmaceuticals and Amgen also utilize stock options and restricted stock units to incentivize their directors and key employees.
• The vesting schedules, typically ranging from one to four years, are designed to promote long-term commitment and alignment with shareholder interests.

Stakeholder Impact

• The grant of stock options and restricted stock units can positively impact shareholders by aligning the director's interests with the company's long-term success.

Key Dates